Cardiff Oncology Inc (CRDF)

$2.23 +0.02 (0.90%)
Market Cap 147.02M
Revenue (ttm) 680,000.00
Net Income (ttm) -45.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,680.88%
Debt to Equity Ratio 0.00
Volume 787,300
Avg Vol 944,388
Day's Range N/A - N/A
Shares Out 66.53M
Stochastic %K 36%
Beta 1.62
Analysts Strong Sell
Price Target $10.50

Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 952 7570
Address:
11055 Flintkote Avenue, San Diego, United States
Bubbarayjr62
Bubbarayjr62 Oct. 25 at 12:44 PM
$CRDF New SA article: https://seekingalpha.com/article/4833398-cardiff-oncology-preparing-for-a-defining-2026
0 · Reply
Huber65
Huber65 Oct. 25 at 4:34 AM
$CRDF doesn’t matter . If data is good , stock is going up up with or with out shorts
1 · Reply
Vavavoom
Vavavoom Oct. 24 at 11:50 PM
$CRDF happy days are here again 🤫
0 · Reply
aaronr
aaronr Oct. 24 at 10:38 PM
$CRDF shorts are covering. Not surprising but kinda disappointing. Was hoping to be at 20m+ into data.
1 · Reply
look2theblue
look2theblue Oct. 24 at 10:10 PM
$CRDF Continuing higher next week. Only cap is that 200DMA just over $3.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 8:59 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CRDF Current Share Price: $2.24 Contracts: $CRDF January 15, 2027 $5 Calls Scale in: $0.53- $0.65 Scale out: $0.82-$1.06 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
mplaster
mplaster Oct. 24 at 5:18 PM
$CRDF this has potential to explode
1 · Reply
mplaster
mplaster Oct. 24 at 4:43 PM
$CRDF all in
0 · Reply
frogman2000
frogman2000 Oct. 24 at 1:04 PM
$CRDF intraday short percentage dropped to 42% yesterday and whallah we went up. All the recent action post July is MM to suppress the PPS. They stand to make a mint when this takes off and they know it. Stay long my friends
4 · Reply
BullRun4
BullRun4 Oct. 24 at 2:54 AM
$CRDF They may announce 10 CR next week!
1 · Reply
Latest News on CRDF
Cardiff Oncology's Promising Cancer Breakthrough Ahead - Why I Choose To Buy

Oct 22, 2025, 7:45 AM EDT - 3 days ago

Cardiff Oncology's Promising Cancer Breakthrough Ahead - Why I Choose To Buy

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Oct 2, 2025, 4:05 PM EDT - 22 days ago

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Aug 28, 2025, 4:05 PM EDT - 2 months ago

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

Jul 30, 2025, 3:27 PM EDT - 3 months ago

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

Cardiff Oncology: Data Update Resolves Some Signals

Jul 30, 2025, 11:32 AM EDT - 3 months ago

Cardiff Oncology: Data Update Resolves Some Signals

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Jul 29, 2025, 4:07 PM EDT - 3 months ago

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Jun 27, 2025, 8:30 AM EDT - 4 months ago

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Cardiff Oncology Names Roger Sidhu as Medical Chief

Jun 17, 2025, 4:39 PM EDT - 4 months ago

Cardiff Oncology Names Roger Sidhu as Medical Chief

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Jun 17, 2025, 4:05 PM EDT - 4 months ago

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Jun 2, 2025, 4:05 PM EDT - 5 months ago

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

May 14, 2025, 9:05 AM EDT - 5 months ago

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 6 months ago

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

May 2, 2025, 3:35 AM EDT - 6 months ago

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Apr 23, 2025, 4:05 PM EDT - 6 months ago

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2025, 4:10 PM EDT - 6 months ago

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Apr 15, 2025, 4:05 PM EDT - 6 months ago

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:10 PM EST - 8 months ago

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Feb 27, 2025, 4:05 PM EST - 8 months ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 24, 2025, 4:05 PM EST - 8 months ago

Cardiff Oncology to Present at Upcoming Investor Conferences

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Feb 20, 2025, 4:05 PM EST - 8 months ago

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Feb 18, 2025, 9:19 AM EST - 8 months ago

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

Dec 14, 2024, 9:00 AM EST - 11 months ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

UI VOD DE ESPR FLNC GASS HII

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Dec 12, 2024, 5:38 AM EST - 11 months ago

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Dec 10, 2024, 5:05 PM EST - 11 months ago

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Dec 10, 2024, 7:20 AM EST - 11 months ago

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Dec 10, 2024, 6:00 AM EST - 11 months ago

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Oct 4, 2024, 1:10 PM EDT - 1 year ago

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Aug 12, 2024, 2:57 PM EDT - 1 year ago

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 11:18 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

Cardiff Oncology to Present at the Jefferies Healthcare Conference

May 29, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at the Jefferies Healthcare Conference

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

May 21, 2024, 11:22 PM EDT - 1 year ago

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

Cardiff Oncology to Present at Upcoming Investor Conferences in May

May 13, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences in May

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

May 3, 2024, 1:30 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

May 2, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar 8, 2024, 7:37 PM EST - 1 year ago

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Mar 6, 2024, 4:05 PM EST - 1 year ago

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 8:06 PM EST - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Feb 29, 2024, 4:07 PM EST - 1 year ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Feb 29, 2024, 4:06 PM EST - 1 year ago

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Feb 29, 2024, 4:05 PM EST - 1 year ago

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

Feb 26, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

Feb 22, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Jan 17, 2024, 10:30 AM EST - 1 year ago

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 4:05 PM EST - 2 years ago

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 9:11 PM EDT - 2 years ago

Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call Transcript

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Nov 2, 2023, 4:05 PM EDT - 2 years ago

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

Bubbarayjr62
Bubbarayjr62 Oct. 25 at 12:44 PM
$CRDF New SA article: https://seekingalpha.com/article/4833398-cardiff-oncology-preparing-for-a-defining-2026
0 · Reply
Huber65
Huber65 Oct. 25 at 4:34 AM
$CRDF doesn’t matter . If data is good , stock is going up up with or with out shorts
1 · Reply
Vavavoom
Vavavoom Oct. 24 at 11:50 PM
$CRDF happy days are here again 🤫
0 · Reply
aaronr
aaronr Oct. 24 at 10:38 PM
$CRDF shorts are covering. Not surprising but kinda disappointing. Was hoping to be at 20m+ into data.
1 · Reply
look2theblue
look2theblue Oct. 24 at 10:10 PM
$CRDF Continuing higher next week. Only cap is that 200DMA just over $3.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 8:59 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CRDF Current Share Price: $2.24 Contracts: $CRDF January 15, 2027 $5 Calls Scale in: $0.53- $0.65 Scale out: $0.82-$1.06 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
mplaster
mplaster Oct. 24 at 5:18 PM
$CRDF this has potential to explode
1 · Reply
mplaster
mplaster Oct. 24 at 4:43 PM
$CRDF all in
0 · Reply
frogman2000
frogman2000 Oct. 24 at 1:04 PM
$CRDF intraday short percentage dropped to 42% yesterday and whallah we went up. All the recent action post July is MM to suppress the PPS. They stand to make a mint when this takes off and they know it. Stay long my friends
4 · Reply
BullRun4
BullRun4 Oct. 24 at 2:54 AM
$CRDF They may announce 10 CR next week!
1 · Reply
jobless44
jobless44 Oct. 23 at 4:53 PM
$CRDF we need more than 3 cents in the pocket
0 · Reply
Neba_
Neba_ Oct. 23 at 3:24 PM
$CRDF Buckle up folks, exciting time are ahead
3 · Reply
Blakeruss1
Blakeruss1 Oct. 23 at 3:04 PM
$CRDF kvro says October 29!!!!
0 · Reply
CallMeEddieMush
CallMeEddieMush Oct. 23 at 1:01 PM
$CRDF none ——dead money
0 · Reply
TheCenterOfNow
TheCenterOfNow Oct. 22 at 10:30 PM
$CRDF what catalysts do we expect in the coming months?
2 · Reply
look2theblue
look2theblue Oct. 22 at 8:49 PM
$CRDF nice recovery in an otherwise ugly market day
0 · Reply
jakeguess
jakeguess Oct. 22 at 8:28 PM
$CRDF Article talks about release coming!! What to Expect During the Q3 Update In the Q3 2025 update, Cardiff Oncology is expected to release new clinical data from its Phase 2 CRDF-004 trial for RAS-mutated metastatic colorectal cancer. I anticipate that this update will probably focus on efficacy signals, safety outcomes, and durability of response for onvansertib combined with standard therapy.
2 · Reply
jakeguess
jakeguess Oct. 22 at 8:27 PM
$CRDF https://seekingalpha.com/article/4831801-cardiff-oncologys-promising-cancer-breakthrough-ahead-why-i-choose-to-buy?utm_campaign=%7Clogin_now_link&utm_medium=email&utm_source=seeking_alpha
0 · Reply
PSDL75
PSDL75 Oct. 22 at 7:33 PM
$CRDF how has this not closed the gap
1 · Reply
GA09
GA09 Oct. 22 at 7:31 PM
$CRDF In a new article in Seeking Alpha the author states that CRDF is expected to announce new/additional data on CRDF-004 on October 29th (when they announce earnings). I do not see that anywhere and CEO has made it clear (multiple times) that they will release complete set of data in Q1 of 2026. Does anyone think otherwise? Thanks!
3 · Reply
JanetBSmellin
JanetBSmellin Oct. 22 at 7:08 PM
$CRDF Thanks for the $2.12 add
0 · Reply
frogman2000
frogman2000 Oct. 22 at 1:52 PM
$CRDF Fintel Short Squeeze score up to 83.96. The past 4 days, off exchange intraday short volume has been massive as a % of the overall volume
1 · Reply